Biopharma
Alteogen strikes $285M deal with GSK subsidiary for innovative cancer drug delivery
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
- By IPP Bureau
| January 23, 2026
Korean biopharma powerhouse Alteogen has announced the inking of an exclusive licensing deal with Tesaro, a subsidiary of GSK, granting the company global rights to ALT-B4.
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market, potentially transforming how patients receive antibody-based therapies.
ALT-B4 is Alteogen’s novel hyaluronidase developed with Hybrozyme technology. Tesaro will use ALT-B4 to develop and commercialize a subcutaneous formulation of dostarlimab, a PD-1 blocking antibody used in cancer treatment.
Under the agreement, Alteogen will receive $20 million upfront and could earn up to $265 million in milestone payments, tied to development, regulatory approvals, and sales targets. The company will also collect royalties on commercial sales and will supply ALT-B4 for clinical and commercial use.
“We are excited to expand our Hybrozyme™ technology by collaborating with Tesaro in the oncology field, and look forward to developing and bringing this potential subcutaneous medicine to market,” said Tae-Yon Chun, CEO of Alteogen.
ALT-B4 is a proprietary human recombinant hyaluronidase enzyme that enables the large-volume subcutaneous delivery of drugs typically given via IV infusion. It works by temporarily breaking down hyaluronan in the extracellular matrix, paving the way for faster, more convenient drug administration.
